
FDA fast tracks geographic atrophy treatment
The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed… Read More

